Why IMU is a multi multi bagger, page-20375

Footnort,

That’s why I find IMU so exciting. We are on an uncharted journey. We just don’t know what will happen next. LC is going to rewrite the FDA’s rule book at this rate.

She calls it a Paradigm shift. Starting with using bio markers to show efficacy rather that waiting years to see increased survival rates.  This will decrease the timeline to approvals for our cancer drugs.

The hopefully if CF33 kills all cancers as YF has told us, they can argue that Cancer is one disease with many symptoms as opposed to 200 different diseases. The FDA approval process probably worked reasonably well will fairly ineffective treatments.  But if a treatment comes along like Vacinia or Oncarlytics that nails the disease as a group then the rules need to be amended.

As with Oncarlytics, IMU is also pushing the envelope with regards to CarT therapies. As Dr Bradley Glover has said “ we now know who are the best vendors “ when supplying donor blood for Azer-Cel. “ we can grade the vendors blood”. That fact will knock out the CarT competition that uses patients own blood. I’d be dumping and shares using this method. Unfortunately for them technologic advancement had beaten them before they got off the blocks.

This is why it’s imperative that IMU present at the JPM Conference. As has been posted many times by DAVY we are at the pointy end now. IMU needs as many eyes on our upcoming results this year.

Attending these conferences  both scientific and investment raises our profiles. That’s what will create opportunities for us.